相关实验视频

Updated: Jun 7, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

我们对TP53突变急性髓性白血病学到了什么?

Moazzam Shahzad¹, Muhammad Kashif Amin², Naval G Daver³

¹Division of Hematology and Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Blood cancer journal

|November 20, 2024

概括

在急性髓性白血病 (AML) 中TP53突变带来了重大治疗挑战. 本综述详细介绍TP53突变AML,其结果,以及开发有效疗法的困难.

科学领域:

在瘤学瘤学.
血液学血液学血液学
分子生物学分子生物学

背景情况:

TP53是一种关键的瘤抑制基因,在人类癌症中经常发生改变.
在5-10%的新型急性髓性白血病 (AML) 病例中观察到TP53突变,特别是在老年人和与治疗相关的AML中.
突变TP53的AML与不良的临床结果和治疗耐药性有关.

研究的目的:

提供AML中TP53突变的全面审查.
讨论与TP53突变相关的临床影响和结果,包括等位体负担.
突出TP53突变AML的治疗挑战和当前治疗局限性.

主要方法:

关于AML中的TP53突变的文献综述.
基于TP53突变状态和等位基负荷的临床结果分析.
对TP53突变AML的现有和新兴治疗策略的评估.

主要成果:

TP53突变在AML中的预后不好,常规化疗,低甲基化剂和基于venetoclax的疗法的疗效有限.
全基性造血干细胞移植提供了潜在的治疗方法,但它的成功取决于患者特定的因素.
基于免疫疗法的早期有希望的结果尚未转化为随机试验中的显著临床益处.

结论:

TP53突变AML仍然是一个难以治疗的血液性恶性瘤.
迫切需要针对TP53突变的AML有效的治疗策略.
对新型治疗方式的进一步研究对于改善患者的治疗结果至关重要.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...